Protein targets for anticancer gold compounds: Mechanistic inferences

Anti-Cancer Agents in Medicinal Chemistry

Volumn 11, Issue 10, 2011, Pages 929-939

  Gabbiani, Chiara ^a   Messori, Luigi ^a  

^a UNIVERSITY OF FLORENCE   (Italy)

Author keywords

Cancer; Gold compounds; Metal protein adducts; Proteins

Indexed keywords

ALLOCRYSIN; ANTINEOPLASTIC AGENT; AUOXO1; AUOXO2; AUOXO3; AUOXO4; AUOXO5; AUOXO6; AURANOFIN; AURO BIS(THIOSULFATE); AUROTHIOGLUCOSE; AUROTHIOMALATE; CISPLATIN; GOLD DERIVATIVE; PROTEASOME; PROTEIN KINASE C IOTA; SODIUM AUROTHIOSULFATE; THIOREDOXIN REDUCTASE; UNCLASSIFIED DRUG; ZINC FINGER PROTEIN;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CELL FUNCTION; CYTOTOXICITY; DRUG MECHANISM; DRUG PROTEIN BINDING; ENZYME ACTIVITY; GROWTH INHIBITION; HUMAN; IC 50; NONHUMAN; PROTEIN INTERACTION; PROTEIN TARGETING; STRUCTURE ACTIVITY RELATION;

EID: 80055108291     PISSN: 18715206     EISSN: 18755992     Source Type: Journal    
DOI: 10.2174/187152011797927607     Document Type: Article

References (46)

1. Shaw, CF III. Gold-based therapeutic agents. Chem. Rev., 1999, 99, 2589-2600.
2. Nobili, S.; Mini, E.; Landini, I.; Gabbiani, C.; Casini, A.; Messori, L. Gold compounds as anticancer agents: chemistry, cellular pharmacology, and preclinical studies. Med. Res. Rev., 2010, 30, 550-580.
3. Gold Chemistry. Applications and Future Directions in the Life Sciences. Edited by Fabian Mohr, Wiley 2009.
4. Mohamed, AA; Bruce, AE; Bruce, MR. Cyclic voltammetry of auranofin. Met. Based Drugs, 1999, 6, 233-238.
5. Marzano, C; Ronconi, L; Chiara, F; Giron, MC; Faustinelli, I; Cristofori, P; Trevisan, A; Fregona, D. Gold(III)-dithiocarbamato anticancer agents: Activity, toxicology and histopathological studies in rodents. Int. J. Cancer, 2010, in press.
6. Cattaruzza, L; Fregona, D; Mongiat, M; Ronconi, L; Fassina, A; Colombatti, A; Aldinucci, D. Antitumor activity of gold(III)- dithiocarbamato derivatives on prostate cancer cells and xenografts. Int. J. Cancer, 2011, 128, 206-215.
7. To, YF; Sun, RW; Chen, Y; Chan, VS; Yu, WY; Tam, PK; Che, CM; Lin, CL. Gold(III) porphyrin complex is more potent than cisplatin in inhibiting growth of nasopharyngeal carcinoma in vitro and in vivo. Int. J. Cancer, 2009, 124, 1971-1979.
8. Lum, CT; Yang, ZF; Li, HY; Wai-Yin Sun, R;Fan, ST; Poon, RT;Lin, MC; Che, CM; Kung, HF. Gold(III) compound is a novel chemocytotoxic agent for hepatocellular carcinoma. Int. J. Cancer, 2006, 118, 1527-1538.
9. Mirabelli CK, Sung CM, Zimmerman JP, Hill DT, Mong S, Crooke ST. Biochem. Pharmacol., 1986, 35(9), 1427-1433.
10. Messori, L; Orioli, P; Tempi, C; Marcon, G. Interactions of selected gold(III) complexes with calf thymus DNA. Biochem Biophys. Res. Commun., 2001, 281, 352-360.
11. Casini, A; Kelter, G; Gabbiani, C; Cinellu, MA; Minghetti, G; Fregona, D; Fiebig, HH; Messori, L. Chemistry, antiproliferative properties, tumor selectivity, and molecular mechanisms of novel gold(III) compounds for cancer treatment: a systematic study. J Biol. Inorg. Chem., 2009, 14, 1139-1149.
12. Barnard, P.J.; Berners-Price, S.J. 'Targeting the mitochondrial cell death pathway with gold compounds', Coord. Chem.y Rev., 2007, 251, 1889-1902.
13. Xiao, J; Schliesman, B; Parsons, DJ; Shaw, CF 3rd. Kinetics and Mechanism of the Reaction between Serum Albumin and Auranofin (and Its Isopropyl Analogue) in vitro. Inorg. Chem. 1996, 35, 424-433.
14. Shaw, CF 3rd; Isab, AA; Coffer MT, Mirabelli CK.Gold(I) efflux from auranofin-treated red blood cells. Evidence for a glutathionegold-albumin metabolite. Biochem. Pharmacol., 1990, 40, 1227-1234.
15. Franzman, MA; Barrios, AM. Spectroscopic evidence for the formation of goldfingers. Inorg. Chem., 2008, 47, 3928-3930.
16. Hickey, JL; Ruhayel, RA; Barnard, PJ; Baker, MV; Berners-Price, SJ; Filipovska, A. Mitochondria-targeted chemotherapeutics: the rational design of gold(I) N-heterocyclic carbene complexes that are selectively toxic to cancer cells and target protein selenols in preference to thiols. J. Am. Chem. Soc., 2008, 130, 12570-12571.
17. Zou, J; Taylor, P; Dornan, J; Robinson, SP; Walkinshaw, MD; Sadler, PJ. First Crystal Structure of a Medicinally Relevant Gold Protein Complex. Angew. Chem. Int. Ed. Engl., 2000, 39, 2931- 2934.
18. Maiore, L; Cinellu, MA; Michelucci, E; Moneti, G; Nobili, S; Landini, I; Mini, E; Guerri, A; Gabbiani, C; Messori, L. Structural and solution chemistry, protein binding and antiproliferative profiles of gold(I)/(III) complexes bearing the saccharinato ligand. J. Inorg. Biochem., 2011, 105, 348-55.
19. Krishna, P.; Bhabak, Bhaskar J. Bhuyan and Govindasamy Mugesh, Bioinorganic and medicinal chemistry: aspects of gold(I)- protein complexes Dalton Trans., 2011, 40, 2099-2111.
20. Marcon, G; Messori, L; Orioli, P; Cinellu, MA; Minghetti, G. Reactions of gold(III) complexes with serum albumin. Eur. J. Biochem., 2003, 270, 4655-4661.
21. Casini, A; Hartinger, C; Gabbiani, C; Mini, E; Dyson, PJ; Keppler, BK; Messori, L. Gold(III) compounds as anticancer agents: relevance of gold-protein interactions for their mechanism of action. J. Inorg. Biochem., 2008, 102, 564-575.
22. Balerna, A; Ascone, I; Castellano, C; Gabbiani, C; Casini, A; Marchioni, C; Jaouen, G; Congiu Castellano, A. X-ray absorption spectroscopy studies of the adducts formed between cytotoxic gold compounds and two major serum proteins. J. Biol. Inorg. Chem., 2011 16, 491-499.
23. Casini, A; Cinellu, MA; Minghetti, G; Gabbiani, C; Coronnello, M; Mini, E; Messori L. Structural and solution chemistry, antiproliferative effects, and DNA and protein binding properties of a series of dinuclear gold(III) compounds with bipyridyl ligands. J. Med. Chem., 2006, 49, 5524-5531.
24. Wai-Yin Sun R., Che C.-M. The anti-cancer properties of gold(III) compounds with dianionic porphyrin and tetradentate ligands Coord. Chem. Rev., 2009, 253, 1682-1691.
25. Sun, RW; Li, CK; Ma, DL; Yan, JJ; Lok, CN; Leung, CH; Zhu, N; Che, CM Stable anticancer gold(III)-porphyrin complexes: effects of porphyrin structure. Chemistry. 2010, 16, 3097-3113.
26. Gromer, S; Urig, S; Becker, K. The thioredoxin system-from science to clinic. Med Res Rev. 2004, 24, 40-89.
27. Arnér, ES. Focus on mammalian thioredoxin reductases-important selenoproteins with versatile functions. Biochim. Biophys. ACTA. 2009, 1790, 495-526.
28. Bindoli, A; Rigobello, M.P.; Scutari G., Gabbiani, C.; Casini, A.; Messori, L. Thioredoxin reductase: A target for gold compounds acting as potential anticancer drugs. Coord. Chem. Rev., 2009, 253, 1692-1707.
29. Pratesi, A; Gabbiani, C; Ginanneschi, M; Messori, L. Reactions of medicinally relevant gold compounds with the C-terminal motif of thioredoxin reductase elucidated by MS analysis. Chem. Commun. (Camb). 2010, 46, 7001-7003.
30. [Mastrobuoni, G.; Sorrentino, S.; Dani, B.; Rigobello, M. P.; Bindoli, A.; Cinellu, M. A.; Pieraccini, G.; Messori, L., Casini. A. Thioredoxin reductase, an emerging target for anticancer metallodrugs. Med.Chem.Comm, 2011, in press.
31. [Gallastegui, N; Groll, M. The 26S proteasome: assembly and function of a destructive machine. Trends Biochem. Sci. 2010, 35, 634-642.
32. Chen, D; Dou, QP. The ubiquitin-proteasome system as a prospective molecular target for cancer treatment and prevention. Curr. Protein Pept. Sci., 2010, 11, 459-470.
33. Ronconi, L; Aldinucci, D; Dou, QP; Fregona, D. Latest insights into the anticancer activity of gold(III)-dithiocarbamato complexes. Anticancer Agents Med Chem., 2010, 10, 283-292.
34. Milacic, V; Dou, QP. The tumor proteasome as a novel target for gold(III) complexes: implications for breast cancer therapy. Coord Chem Rev. 2009, 253, 1649-1660.
35. Mellor, H; Parker, PJ The extended protein kinase C superfamily. Biochem. J., 1998, 332, 281-292.
36. Murray, NR; Kalari, KR; Fields, AP. Protein kinase C expression and oncogenic signaling mechanisms in cancer. J. Cell Physiol., 2011, 226, 879-887.
37. Fields, AP; Frederick, LA; Regala, RP. Targeting the oncogenic protein kinase Ciota signalling pathway for the treatment of cancer. Biochem Soc Trans., 2007, 35, 996-1000.
38. Stallings-Mann, M; Jamieson, L; Regala, RP; Weems, C; Murray, NR; Fields, AP. A novel small-molecule inhibitor of protein kinase Ciota blocks transformed growth of non-small-cell lung cancer cells. Cancer Res., 2006, 66, 1767-1774.
39. Regala, RP; Thompson, EA; Fields, AP. Atypical protein kinase C iota expression and aurothiomalate sensitivity in human lung cancer cells. Cancer Res., 2008, 68, 5888-5895.
40. Larabee JL, Hocker JR, Hanas JS. Mechanisms of aurothiomalate-Cys2His2 zinc finger interactions Chem. Res. Toxicol., 2005 18,1943-154
41. [Franzman MA, Barrios AM Spectroscopic evidence for the formation of goldfingers. Inorg. Chem., 2008, 473928-473930.
42. de Paula QA, Mangrum JB, Farrell NP Zinc finger proteins as templates for metal ion exchange: Substitution effects on the Cfinger of HIV nucleocapsid NCp7 using M(chelate) species (M=Pt, Pd, Au). J. Inorg. Biochem., 2009,103, 1347-1354.
43. Mendes F, Groessl M, Nazarov AA, Tsybin YO, Sava G, Santos I, Dyson PJ, Casini A.Metal-based inhibition of poly(ADP-ribose) polymerase--the guardian angel of DNA. J. Med. Chem., 2011 54, 2196-2206
44. Gabbiani, C; Magherini, F; Modesti, A; Messori, L. Proteomic and metallomic strategies for understanding the mode of action of anticancer metallodrugs. Anticancer Agents Med. Chem., 2010, 10, 324-337.
45. Wang, Y; He, QY; Che CM, Chiu JF. Proteomic characterization of the cytotoxic mechanism of gold (III) porphyrin 1a, a potential anticancer drug. Proteomics, 2006, 6, 131-142.
46. Magherini, F; Modesti, A; Bini, L; Puglia, M; Landini, I; Nobili, S; Mini, E, Cinellu, MA; Gabbiani, C; Messori, L. Exploring the biochemical mechanisms of cytotoxic gold compounds: a proteomic study. J. Biol. Inorg. Chem., 2010, 15, 573-582.